Oriva Therapeutics Debuts with the Support of Asabys to Advance New Treatments in Women’s Health

Barcelona, January 22, 2026 – Oriva Therapeutics, a company dedicated to developing first-in-class and best-in-class treatments for chronic and prevalent diseases affecting women, has announced its establishment and the closing of a pre-seed financing round with Asabys Partners through its Sabadell Asabys II fund.

Oriva Therapeutics has integrated two advanced assets from Oncostellae and Medibiofarma, positioning itself as one of the first clinical-stage biotech companies in Spain with an exclusive focus on developing innovative drugs for chronic gynecological diseases. The first asset, ORV-362, is a non-hormonal, disease-modifying therapy for the treatment of endometriosis, a condition affecting approximately 10% of women and girls of reproductive age worldwide. ORV-362 is compatible with conception and has demonstrated a favorable safety profile in clinical trials conducted by the originating company. The program entered Phase I in healthy women in January 2026.

The second program, ORV-499, is aimed at treating uterine fibroids, the most common benign gynecological tumors, and is expected to enter Phase I clinical trials in the first quarter of 2027. Both assets act on validated therapeutic targets and are based on innovative chemistry that clearly differentiates them from existing market options.

This financing from Sabadell Asabys II will allow Oriva Therapeutics to establish its initial team and facilities, as well as advance both programs to Phase II clinical trials. Asabys has successfully backed other spin-offs and early-stage companies such as Ona Therapeutics, Origo Biopharma, SpliceBio, Inbrain Neuroelectronics, Nuage Therapeutics, OrikineBio, and ALLOX.

Julio Castro, co-founder of Oncostellae and Medibiofarma, stated that the company is very satisfied with the innovative agreement reached with Asabys. He noted that the two assets generated and developed within the parent companies will find a new life at Oriva, benefiting from new funding and a novel therapeutic approach.

Clara Campàs, Managing Partner at Asabys, added that chronic gynecological diseases such as endometriosis and uterine fibroids have historically been underfunded and overlooked, despite their profound impact on women’s health. She emphasized Asabys’ excitement in supporting Oriva to advance these first-in-class and best-in-class programs toward clinical development and ultimately to patients. Campàs highlighted the high medical need, renewed industry interest in chronic women’s health indications, and the extraordinary chemistry developed by Julio Castro and his team, positioning Oriva as a highly promising investment for the Sabadell Asabys II fund.

About Oriva Therapeutics
Oriva Therapeutics is a clinical-stage women’s health biotech company focused on developing first-in-class and best-in-class therapies for chronic gynecological diseases with high unmet medical needs. Based in Barcelona, the company was founded to advance innovative approaches aimed at improving both clinical outcomes and quality of life for women. Oriva’s portfolio centers on two advanced programs in endometriosis and uterine fibroids, based on innovative chemistry targeting validated biological pathways and clearly differentiated from existing therapeutic options. The company is financed by Sabadell Asabys II, a fund managed by Asabys Partners, and relies on assets originated from Oncostellae and Medibiofarma.

About Asabys Partners
Asabys Partners is a Barcelona-based venture capital firm specializing in health and life sciences innovation, including biotechnology, medical technology, and digital health. Founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, the firm is supported by Alantra and Banc Sabadell as an anchor investor. Asabys aims to support highly innovative and transformative technologies that address unmet medical needs. The firm manages over €400 million in assets and has 24 companies in its portfolio. Asabys positions itself not only as an investor but as an active and collaborative partner to its portfolio companies, with the goal of translating disruptive science into tangible results for patients. Investments in the company are made through the Sabadell Asabys Health Innovation Investments II, FCR, and Sabadell Asabys Health Innovation Investments 2B, SCR, S.A. vehicles. www.asabys.com